Cargando…
Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients
Since 2010, the European Medicines Agency (EMA) has provided access to clinical study reports (CSRs). We requested CSRs for randomized controlled trials (RCTs) of erythropoiesis-stimulating agents (ESAs) in cancer patients from EMA and identified RCT publications with literature searches. We assesse...
Autores principales: | Rohner, Eliane, Grabik, Michael, Tonia, Thomy, Jüni, Peter, Pétavy, Frank, Pignatti, Francesco, Bohlius, Julia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724886/ https://www.ncbi.nlm.nih.gov/pubmed/29228059 http://dx.doi.org/10.1371/journal.pone.0189309 |
Ejemplares similares
-
Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data
por: Bohlius, J, et al.
Publicado: (2014) -
Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency
por: Collignon, Olivier, et al.
Publicado: (2018) -
Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014) -
The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
por: Michaleas, S., et al.
Publicado: (2022) -
Access to regulatory data from the European Medicines Agency: the times they are a-changing
por: Wieseler, Beate, et al.
Publicado: (2012)